Relationship between UGT1A1 * 28 gene polymorphism and delayed diarrhea caused by FOLFIRI treatment
10.3760/cma.j.issn.1673-422X.2015.02.006
- VernacularTitle:UGT1A1*28基因多态性与FOLFIRI方案化疗致迟发性腹泻的关系
- Author:
Deng LI
;
Yan WANG
;
Lu WANG
;
Yiping ZHU
- Publication Type:Journal Article
- Keywords:
Drug toxicity;
UDP glucuronosyltransferase 1 family,polypeptide A1;
Irinotecan
- From:
Journal of International Oncology
2015;42(2):99-102
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the relationship between UDP-glucuronosyltransferase 1A1 (UGT1A1)gene polymorphism and delayed diarrhea caused by FOLFIRI treatment.Methods Two hundred and one blood samples were taken from patients with metastatic digestive tract tumor before chemotherapy by FOLFIRI and then the UGT1A1 * 28 genetic polymorphism was performed.All the cases treated with FOLFIRI were chosen to be observed and recorded by situation of the delayed diarrhea during chemotherapy,and to analyze the relationship between UGT1A1 * 28 genetic polymorphism and grade 3 and 4 delayed diarrhea.Results The distributions of the genotypes in 201 metastatic digestive tract tumor patients were as follows:UGT1A1 * 28 wild-type genotype TA6/6 (155,77.11％),heterozygous genotype TA6/7 together with homozygous genotype TA7/7 (46,22.89％).In the 201 cases,the incidences of grade 1 and 2 delayed diarrhea in the patients carrying wild-type genotype and mutant type were respectively 45.16％ (70/155),39.13％ (18/46).The incidences of grade 3 and 4 delayed diarrhea were respectively 9.68％ (15/155),19.57％ (9/46),with no statistical difference (x2 =3.318,P =0.190).Conclusion The UGT1A1 * 28 polymorphism TA6/7 or TA7/7 can not increase the risk of grade 3 or more severe delayed diarrhea for the patients with metastatic digestive tract tumor after receiving FOLFIRI treatment.
